- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.09. | Biotech Stocks At 52-Week Highs - RenovoRx +15%, Evolus, Crinetics Pharmaceuticals, Apogee Therapeutics | 741 | AFX News | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - The following biotech stocks reached a 52-week high on August 31, 2026, driven by achieving new regulatory milestones or an upcoming acquisition.RenovoRx... ► Artikel lesen | |
| 31.08. | Biotech Stocks At 52-Week Highs - RenovoRx +12%, BlossomHill Therapeutics, Revvity, AtriCure, Biofrontera Inc. | 554 | AFX News | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 28, 2026, as various clinical trials reported initial data and companies reached certain regulatory milestones.RenovoRx... ► Artikel lesen | |
| 25.08. | RenovoRx, Inc.: RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP Platform's Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer | 2 | GlobeNewswire (USA) | ||
| 21.08. | RenovoRx regains Nasdaq compliance | 1 | Seeking Alpha | ||
| RENOVORX Aktie jetzt für 0€ handeln | |||||
| 21.08. | RenovoRx regains Nasdaq minimum bid price compliance | 1 | Investing.com | ||
| 21.08. | RenovoRx erfüllt wieder NASDAQ-Mindestkursanforderung | 2 | Investing.com Deutsch | ||
| 21.08. | RenovoRx, Inc.: RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | 241 | GlobeNewswire (Europe) | MOUNTAIN VIEW, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and... ► Artikel lesen | |
| 20.08. | RenovoRx, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.08. | RenovoRx receives U.S. patent allowance for cancer device | 4 | Investing.com | ||
| 20.08. | RenovoRx, Inc.: RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment | 250 | GlobeNewswire (Europe) | MOUNTAIN VIEW, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and... ► Artikel lesen | |
| 13.08. | RenovoRx, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 12.08. | RenovoRx, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 11.08. | RenovoRx, Inc.: RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer | 1.185 | GlobeNewswire (Europe) | MOUNTAIN VIEW, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and... ► Artikel lesen | |
| 11.08. | EXCLUSIVE: Renovorx Advances Its Targeted Pancreatic Cancer Therapy, Pivotal Data Expected in 2027 | 1 | Benzinga.com | ||
| 06.08. | RenovoRx, Inc.: RenovoRx Announces First Commercial Clinical Use of RenovoCath in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors | 278 | GlobeNewswire (Europe) | MOUNTAIN VIEW, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and... ► Artikel lesen | |
| 04.08. | RenovoRx, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.06. | RenovoRx, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 30.06. | RenovoRx, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.05. | RenovoRx Says FDA Grants Orphan Drug Status For Oxaliplatin To Treat Pancreatic Cancer | 1 | RTTNews | ||
| 28.05. | RenovoRx, Inc.: RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer | 550 | GlobeNewswire (Europe) | MOUNTAIN VIEW, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing... ► Artikel lesen |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 85,05 | +0,12 % | Biontech zwischen Euphorie und Rückschlägen | Im Zuge des Covid-Impfstoff-Booms fuhr Biontech Milliardengewinne ein und der Aktienkurs erreichte im August 2021 mit 397 € sein bisheriges Allzeithoch. Während das Impfstoffgeschäft inzwischen operativ... ► Artikel lesen | |
| MODERNA | 120,58 | -0,13 % | Moderna-Aktie: Geht jetzt die Rallye weiter? | Die Moderna-Aktie hat Mitte August eine außergewöhnlich starke Rallye hingelegt und am 18. und 19. August insgesamt rund +211% zugelegt. Nach der anschließenden Konsolidierung meldeten sich die Bullen... ► Artikel lesen | |
| NOVAVAX | 8,750 | -0,11 % | Novavax-Aktie: Ist das im Zuge von Moderna die nächste Kursrakete? Die MRNA Krebs-Impfstoff-Welle hat begonnen! | © Foto: Tara Winstead auf PexelsBei Moderna ging es zuletzt steil nach oben, sehr spektakulär. Und jetzt könnte Novavax nachziehen. Der Grund bei Moderna ist ein Paukenschlag aus der Krebsforschung... ► Artikel lesen | |
| BIOGEN | 182,60 | -0,11 % | Biogen Inc.: Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) | -4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with... ► Artikel lesen | |
| ILLUMINA | 183,12 | +0,79 % | S&P Dow Jones Indices: Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600 | NEW YORK, Sept. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 47,140 | +0,03 % | Why CRISPR Therapeutics Stock Rocked the Market Last Month | ||
| PALATIN TECHNOLOGIES | 12,590 | -0,71 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 1,158 | +0,70 % | Ocugen, Inc. - 8-K, Current Report | ||
| VIKING THERAPEUTICS | 29,000 | 0,00 % | 3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're Wrong | ||
| NUREXONE BIOLOGIC | 0,391 | -1,76 % | NurExone Biologic: Attacke auf den Hauptwiderstand! | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,150 | +1,64 % | PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test | ||
| REDHILL BIOPHARMA | 0,658 | +1,22 % | RedHill Biopharma Ltd.: RedHill Divests Talicia to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities | Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's commercial business toward new and larger product opportunities, revenue growth and an accelerated... ► Artikel lesen | |
| ATAIBECKLEY | 6,350 | +0,79 % | AtaiBeckley Inc. - 8-K, Current Report | ||
| TWIST BIOSCIENCE | 110,25 | +0,14 % | Cathie Wood's ARK sees major stock moves with Robinhood and Twist Bioscience | ||
| NOVOCURE | 15,580 | +7,45 % | Novocure Announces Upcoming Investor Events | Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events.
Wells Fargo 21st Annual Healthcare Conference, September 9, 2026: Frank Leonard, Chief... ► Artikel lesen |
RENOVORX INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,180 Euro und damit -0,91 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RENOVORX INC finden Sie auf Wallstreet Online.